IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-34728-1.html
   My bibliography  Save this article

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

Author

Listed:
  • Philipe Gobeil

    (Medicago Inc.)

  • Stéphane Pillet

    (Medicago Inc.)

  • Iohann Boulay

    (Medicago Inc.)

  • Nathalie Charland

    (Medicago Inc.)

  • Aurélien Lorin

    (Medicago Inc.)

  • Matthew P. Cheng

    (The Research Institute of the McGill University Health Centre)

  • Donald C. Vinh

    (The Research Institute of the McGill University Health Centre)

  • Philippe Boutet

    (GlaxoSmithKline (Vaccines))

  • Robbert Most

    (GlaxoSmithKline (Vaccines)
    BioNTech)

  • François Roman

    (GlaxoSmithKline (Vaccines))

  • Maria Angeles Ceregido

    (GlaxoSmithKline (Vaccines))

  • Nathalie Landry

    (Medicago Inc.)

  • Marc-André D’Aoust

    (Medicago Inc.)

  • Brian J. Ward

    (Medicago Inc.
    The Research Institute of the McGill University Health Centre)

Abstract

As the SARS-CoV-2 pandemic evolves, vaccine evaluation needs to include consideration of both durability and cross-reactivity. This report expands on previously reported results from a Phase 1 trial of an AS03-adjuvanted, plant-based coronavirus-like particle (CoVLP) displaying the spike (S) glycoprotein of the ancestral SARS-CoV-2 virus in healthy adults (NCT04450004). Humoral and cellular responses against the ancestral strain were evaluated 6 months post-second dose (D201) as secondary outcomes. Independent of dose, all vaccinated individuals retain binding antibodies, and ~95% retain neutralizing antibodies (NAb). Interferon gamma and interleukin-4 responses remain detectable in ~94% and ~92% of vaccinees respectively. In post-hoc analyses, variant-specific (Alpha, Beta, Delta, Gamma and Omicron) NAb were assessed at D42 and D201. Using a live virus neutralization assay, broad cross-reactivity is detectable against all variants at D42. At D201, cross-reactive antibodies are detectable in almost all participants against Alpha, Gamma and Delta variants (94%) and the Beta variant (83%) and in a smaller proportion against Omicron (44%). Results are similar with the pseudovirion assay. These data suggest that two doses of 3.75 µg CoVLP+AS03 elicit a durable and cross-reactive response that persists for at least 6 months post-vaccination.

Suggested Citation

  • Philipe Gobeil & Stéphane Pillet & Iohann Boulay & Nathalie Charland & Aurélien Lorin & Matthew P. Cheng & Donald C. Vinh & Philippe Boutet & Robbert Most & François Roman & Maria Angeles Ceregido & N, 2022. "Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34728-1
    DOI: 10.1038/s41467-022-34728-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-34728-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-34728-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jackson S. Turner & Jane A. O’Halloran & Elizaveta Kalaidina & Wooseob Kim & Aaron J. Schmitz & Julian Q. Zhou & Tingting Lei & Mahima Thapa & Rita E. Chen & James Brett Case & Fatima Amanat & Adriana, 2021. "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses," Nature, Nature, vol. 596(7870), pages 109-113, August.
    2. Katherine McMahan & Jingyou Yu & Noe B. Mercado & Carolin Loos & Lisa H. Tostanoski & Abishek Chandrashekar & Jinyan Liu & Lauren Peter & Caroline Atyeo & Alex Zhu & Esther A. Bondzie & Gabriel Dagott, 2021. "Correlates of protection against SARS-CoV-2 in rhesus macaques," Nature, Nature, vol. 590(7847), pages 630-634, February.
    3. Heidi Ledford, 2022. "‘Killer’ immune cells still recognize Omicron variant," Nature, Nature, vol. 601(7893), pages 307-307, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Vincent Pavot & Catherine Berry & Michael Kishko & Natalie G. Anosova & Lu Li & Tim Tibbitts & Dean Huang & Alice Raillard & Sylviane Gautheron & Cindy Gutzeit & Marguerite Koutsoukos & Roman M. Chicz, 2023. "Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates," Nature Communications, Nature, vol. 14(1), pages 1-8, December.
    2. Li Wang & Markus H. Kainulainen & Nannan Jiang & Han Di & Gaston Bonenfant & Lisa Mills & Michael Currier & Punya Shrivastava-Ranjan & Brenda M. Calderon & Mili Sheth & Brian R. Mann & Jaber Hossain &, 2022. "Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    3. Hassen Kared & Asia-Sophia Wolf & Amin Alirezaylavasani & Anthony Ravussin & Guri Solum & Trung The Tran & Fridtjof Lund-Johansen & John Torgils Vaage & Lise Sofie Nissen-Meyer & Unni C. Nygaard & Ola, 2022. "Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Dapeng Li & David R. Martinez & Alexandra Schäfer & Haiyan Chen & Maggie Barr & Laura L. Sutherland & Esther Lee & Robert Parks & Dieter Mielke & Whitney Edwards & Amanda Newman & Kevin W. Bock & Mahn, 2022. "Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    5. Eva Stadler & Martin T. Burgess & Timothy E. Schlub & Shanchita R. Khan & Khai Li Chai & Zoe K. McQuilten & Erica M. Wood & Mark N. Polizzotto & Stephen J. Kent & Deborah Cromer & Miles P. Davenport &, 2023. "Monoclonal antibody levels and protection from COVID-19," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    6. Ramon Roozendaal & Laura Solforosi & Daniel J. Stieh & Jan Serroyen & Roel Straetemans & Anna Dari & Muriel Boulton & Frank Wegmann & Sietske K. Rosendahl Huber & Joan E. M. van der Lubbe & Jenny Hend, 2021. "SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques," Nature Communications, Nature, vol. 12(1), pages 1-10, December.
    7. Guiomar Casado-Fernández & Magdalena Corona & Montserrat Torres & Adolfo J. Saez & Fernando Ramos-Martín & Mario Manzanares & Lorena Vigón & Elena Mateos & Francisco Pozo & Inmaculada Casas & Valentín, 2023. "Sustained Cytotoxic Response of Peripheral Blood Mononuclear Cells from Unvaccinated Individuals Admitted to the ICU Due to Critical COVID-19 Is Essential to Avoid a Fatal Outcome," IJERPH, MDPI, vol. 20(3), pages 1-19, January.
    8. Emanuele Andreano & Ida Paciello & Silvia Marchese & Lorena Donnici & Giulio Pierleoni & Giulia Piccini & Noemi Manganaro & Elisa Pantano & Valentina Abbiento & Piero Pileri & Linda Benincasa & Ginevr, 2022. "Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    9. Payton A.-B. Weidenbacher & Mrinmoy Sanyal & Natalia Friedland & Shaogeng Tang & Prabhu S. Arunachalam & Mengyun Hu & Ozan S. Kumru & Mary Kate Morris & Jane Fontenot & Lisa Shirreff & Jonathan Do & Y, 2023. "A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    10. Julia Merkenschlager & Riza-Maria Berz & Victor Ramos & Maximilian Uhlig & Andrew J. MacLean & Carla R. Nowosad & Thiago Y. Oliveira & Michel C. Nussenzweig, 2023. "Continually recruited naïve T cells contribute to the follicular helper and regulatory T cell pools in germinal centers," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    11. Jernej Pušnik & Jasmin Zorn & Werner O. Monzon-Posadas & Kathrin Peters & Emmanuil Osypchuk & Sabine Blaschke & Hendrik Streeck, 2024. "Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    12. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    13. Arnaud Desrosiers & Rabeb Mouna Derbali & Sami Hassine & Jérémie Berdugo & Valérie Long & Dominic Lauzon & Vincent De Guire & Céline Fiset & Luc DesGroseillers & Jeanne Leblond Chain & Alexis Vallée-B, 2022. "Programmable self-regulated molecular buffers for precise sustained drug delivery," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    14. Iris N. Pardieck & Tetje C. van der Sluis & Esmé T. I. van der Gracht & Dominique M. B. Veerkamp & Felix M. Behr & Suzanne van Duikeren & Guillaume Beyrend & Jasper Rip & Reza Nadafi & Elham Beyranvan, 2022. "A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    15. Rúbens Prince dos Santos Alves & Julia Timis & Robyn Miller & Kristen Valentine & Paolla Beatriz Almeida Pinto & Andrew Gonzalez & Jose Angel Regla-Nava & Erin Maule & Michael N. Nguyen & Norazizah Sh, 2024. "Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice," Nature Communications, Nature, vol. 15(1), pages 1-20, December.
    16. Ivan T. Lee & Raffael Nachbagauer & David Ensz & Howard Schwartz & Lizbeth Carmona & Kristi Schaefers & Andrei Avanesov & Daniel Stadlbauer & Carole Henry & Ren Chen & Wenmei Huang & Daniela Ramirez S, 2023. "Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    17. Elham Khatamzas & Markus H. Antwerpen & Alexandra Rehn & Alexander Graf & Johannes Christian Hellmuth & Alexandra Hollaus & Anne-Wiebe Mohr & Erik Gaitzsch & Tobias Weiglein & Enrico Georgi & Clemens , 2022. "Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    18. Leander Witte & Viren A. Baharani & Fabian Schmidt & Zijun Wang & Alice Cho & Raphael Raspe & Camila Guzman-Cardozo & Frauke Muecksch & Marie Canis & Debby J. Park & Christian Gaebler & Marina Caskey , 2023. "Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    19. Zixiang Wang & Shourong Wang & Junchao Qin & Xiyu Zhang & Gang Lu & Hongbin Liu & Haiyang Guo & Ligang Wu & Victoria O. Shender & Changshun Shao & Beihua Kong & Zhaojian Liu, 2022. "Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12," Nature Communications, Nature, vol. 13(1), pages 1-18, December.
    20. Youyi Fong & Yunda Huang & David Benkeser & Lindsay N. Carpp & Germán Áñez & Wayne Woo & Alice McGarry & Lisa M. Dunkle & Iksung Cho & Christopher R. Houchens & Karen Martins & Lakshmi Jayashankar & F, 2023. "Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial," Nature Communications, Nature, vol. 14(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34728-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.